Bayer Aktiengesellschaft

Bayer Animal Health Gmbh

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Elanco US Inc.

Bayer Healthcare Aktiengesellschaft

Venkata-Rangarao Kanikanti

Achim Harder

Hans-Juergen Hamann

Roland Rupp

Patrick Billian

Jan-Olav Henck

Takaaki Nishioka

Hitoshi Ichihashi

Chika Taniguchi

Yoshifumi Katakawa

Peter Deuringer

Wolfgang Weber

Peter Kurka

Peter Kleinebudde

Heino Stab

Petra Lange

Georg Schulte

Peter Serno

Andreas Ohm

Gunther Penners

Claus Weisemann

Hans-Jürgen Hamann

Stefan Kettelhoit

Erich Brendel

Thomas Bach

Axel Schmidt

Ernst Chantraine

J&uuml;rgen Sdebik

Wolfgang Muck

Gerd Toppel

Heino Staβ

Gertraut Altreuther

Sabine Bongaerts

Patrick Bosché

Michael Träubel

Michael Traeubel

Hans-Jurgen Hamann

Patrick Bosche

Heino Stass

Andrea Michalk

Martina Rehagen

Rieke Witzleb

Claudia Reitz

The present invention refers to a pharmaceutical preparation () comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation () comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation () is provided in a multi-layer structure such, that the first composition is provided in a first layer () and the second composition is provided in a second layer (), wherein the first layer () and the second layer () are separated by a barrier layer () being provided between the first layer () and the second layer ().

Pharmaceutical preparation and method for its manufacture

The present invention relates to tablets for animals, having improved acceptance and good storage stability.

Tablets with improved acceptance and good storage stability

The invention relates to preparations comprising amorphous emodepside in a polyvinylpyrrolidone matrix, pharmaceuticals comprising such preparations, and their use against endoparasites in animals or humans.

Preparations containing amorphous emodepside

The present invention generally relates to soft chewables, especially suitable for delivering active ingredients to animals and processes for the preparation thereof. In various embodiments, the soft chewable comprises a pharmaceutically effective amount of at least one active ingredient, a flavoring agent, a disintegrant, a humectant, an antioxidant, a preservative, and water. In accordance with preferred embodiments, the soft chewable is essentially free of starch, oil, glycols, waxes, and soy products.

Non-starch based soft chewables

The present invention relates to an orally administrable preparation comprising a quinolone antibiotic which releases the active compound with a delay.

Sustained-release preparations of quinolone antibiotics

The invention relates to flavoring-containing pharmaceutical formulations with improved pharmaceutical properties, and to process for the production thereof.

Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties

Method of preparing sustained-release preparations of quinolone antibiotics

The present invention relates to transdermally applicable compositions comprising cyclic depsipeptides and/or praziquantel, and to their preparation and their use for controlling endoparasites.

Endoparasiticidal compositions for topical application

Sustained-release preparations of quinolone antibiotics and method for preparation thereof

The present invention relates to orally administrable multiple-unit sustained-release dose forms having controlled agitation-independent release of active compound and processes for their production using a selected erodable hydrophilic polymer (HPC) and a limitation of the maximum size of the active compound-containing polymer particles to &lE;3 mm.

Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same

The present invention relates to stable quick-release extrudates that contain low-viscosity hydroxypropylcellulose and at least one active ingredient. This invention also relates to a method for preparing said extrudates without the use of solvents as well as to the use of said extrudates in the production of quick-release preparations.

Quick-release extrudates, method for preparing the same and compositions obtained from said extrudates

The invention relates to pharmaceutical preparations having controlled release of active compound and to processes for their preparation, in particular for poorly soluble active compounds having problematic bioavailability.

Pharmaceutical preparations having controlled release of active compound

The invention relates to a special process for the preparation of stable, solid medicament formulations of high bioavailability and with controlled release comprising sparingly soluble active compounds and polymeric auxiliaries, and to the formulations thus prepared.

Process for the preparation of medicament formulations with controlled

Growing community of inventors

Leverkusen, Germany

Venkata-Rangarao Kanikanti